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Abstract
Oxidative stress (OS) plays an important role in atherogenesis and since glutathione S-transferases (GSTs) provide
protection against OS, we have tested the hypothesis that deletion polymorphisms in two GSTs (GSTM1 and
GSTT1) may affect the risk of developing atherosclerosis. A total of 382 individuals (200 patients with atherosclerosis
and 182 healthy controls) were included in this association study. Genomic DNA was isolated from peripheral blood
cells or from buccal epithelial cells and genotyping was performed using multiplex-PCR or real-time PCR methods.
GSTM1 null genotype was significantly more frequent in atherosclerotic patients than in controls (52.0% vs 34.1%)
and individuals with the GSTM1 null genotype had an approximately 2-fold increase in atherosclerosis risk (OR: 2.1,
95%CI=1.39-3.17, P=0.0004). GSTT1 null genotype alone did not show a statistically significant effect on athero-
sclerosis risk modulation, but the association approached significance (OR: 1.57, 95%CI=0.94-2.64, P=0.08). The
combined analysis showed that the presence of both genes had a protective effect against atherosclerosis
(OR=0.55, 95%CI=0.37-0.83, P=0.005) while double null genotypes led to a robust atherosclerosis risk increase
(OR: 8.14, 95%CI= 2.41-27.51, P < 0.0001). This study demonstrated that the GSTM1 null and combined
GSTM1/GSTT1 null genotypes are susceptibility factors for development of atherosclerosis in a Serbian population.
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Introduction
Substantial data indicate that oxidative stress (OS) is
involved in the development of atherosclerosis. Athero-
genesis, one of the main risk factors for cardiovascular dis-
eases (CVD), is initiated by oxidation of the low-density li-
poprotein (LDL) and by impairment of oxidative
stress-antioxidant balance. Conventional risk factors for
CVD, including diabetes mellitus, hypercholesterolemia or
dyslipidemia, hypertension and smoking, are generally re-
lated to OS. Patients with CVD commonly have at least one
identifiable risk factor but many ischemic events occur in
the absence of risk factors (Futterman and Lemberg, 1998).
For this reason, there has been a deep interest in finding
additional markers of oxidative stress, including gene poly-
morphisms, which might be used as predictors of disease
risk.
Reactive oxygen species (ROS) produced by endo-
thelial cells, smooth muscle cells (SMCs) and macrophages
oxidize LDL in the subendothelial space, at the sites of en-
dothelial damage, initiating events that culminate in the for-
mation of atheroma. Some antioxidant enzymes such as
superoxide dismutase and catalase directly eliminate ROS,
while gluthatione S- transferases (GSTs) detoxify second-
ary cytotoxic metabolites of ROS. As phase II biotrans-
formation enzymes, GSTs protect cellular macromolecules
by catalyzing the conjugation of reduced glutathione
(GSH) to exogenous and endogenous electrophilic com-
pounds, which are, respectively, the results of either xeno-
biotic breakdown, or oxidative damage to lipids and DNA
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(Douglas, 1987; Berhane et al., 1994; Hayes and McLellan,
1999). Specific intracellular localization of the members of
this GST superfamily has facilitated their categorization
into three distinct groups: cytosolic, mitochondrial and
microsomal GSTs. Cytosolic GSTs represent the largest
family, and genes encoding these soluble isoforms are
spread throughout the genome (Hayes and Strange, 2000).
Polymorphisms in GST genes affect the activity of encoded
enzymes and consequently have functional effects on redox
regulation. A variety of polymorphisms have been de-
scribed in the GSTs gene superfamily, but major attention
has been focused on complete deletion polymorphism in
mu (GSTM) and theta (GSTT) subfamilies since they abol-
ish enzymatic activity. Polymorphic variants in the GSTM1
(GSTM1*0) and GSTT1 (GSTT1*0) genes produce either a
functional proteins, i.e. non-null phenotypes (non-deletion
alleles or heterozygous deletion) or result in the complete
absence of enzymes, i.e. null phenotypes (homozygous de-
letion or null genotype) (Eaton and Bammler, 1999).
Many conditions have been associated with the dele-
tion polymorphisms in GSTM and GSTT genes, including
asthma (Lima et al., 2010), male infertility (Dordevic et al.,
2010), end-stage renal disease (Suvakov et al., 2013), leu-
kemia (Souza et al., 2008; Nasr et al., 2015) and lung can-
cer (Sharma et al., 2015; Yang et al., 2015), among others.
So far, controversial results have been reported about
the importance of GSTM1 and GSTT1 null genotypes in
atherogenesis in different human populations (Türkanoglu
et al., 2010; Ramprasath et al., 2011; Nørskov et al., 2011;
Santl Letonja et al., 2012; Cora et al., 2013; Yeh et al.,
2013; Mir et al., 2016). This has prompted us to study the
potential role of deletion polymorphisms in GSTM1 and
GSTT1 in predicting the susceptibility to atherosclerosis in
Serbian patients.
Material and Methods
Study population
A total of 382 individuals (200 patients and 182 con-
trols) participated in this case-control study. All partici-
pants were of Serbian ethnicity and unrelated. Patients
presented clinical manifestations of atherosclerosis and had
been treated at Dedinje Cardiovascular Institute (DCI) or
Zvezdara University Medical Center (ZUMC), Belgrade,
Serbia, from 2010 to 2011.
Diagnosis of atherosclerosis was based on medical
history including: presence of coronary heart disease
(CHD), cerebrovascular diseases (CVD), peripheral arte-
rial disease (PAD) and type 2 diabetes mellitus (T2DM).
CHD in patients with previous myocardial infarction and
stable angina pectoris was estimated by coronarography,
whilst carotid atherosclerosis was estimated by high-reso-
lution B-mode ultrasonography HDI, ATL 3500, or accord-
ing to data related to carotid artery surgery. Cerebral
ischemia was diagnosed according to symptoms including
amaurosis fugax, transient ischemic attack and stroke, and
PAD was diagnosed by ankle/brachial index (<0.90) or ac-
cording to previous data about lower extremity arterial sur-
gery. The determination of T2DM was based on values of
glycemia (2 readings of glycemia in 2 consecutive days):
fasting plasma glucose concentration 7.0 mmol/L (126
mg/dL) or glycemia in any random blood sample (regard-
less of meals)  11.1 mmol/L (200 mg/dL) with the pres-
ence of typical diabetes symptoms (polyuria, polydipsia,
weight loss) or based on the value of glycemia during an
oral glucose tolerance test (OGTT): plasma glucose con-
centration during an OGTT in the 120th minute  11.1
mmol/L (200 mg/dL). Blood pressure measurements were
done according to recommendation of the Seventh Report
of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC7)
(Chobanian et al., 2003): participants were considered hy-
pertensive if their average (the mean of at least two mea-
surements) systolic blood pressure (SBP) was 140 mmHg
or higher and/or their average (the mean of at least two
measurements) diastolic blood pressure (DBP) was 90
mmHg or higher (and/or the person used antihypertensive
medications). Hyperlipidemia was diagnosed if a person’s
complete lipid profile had total cholesterol level 6.20
mmol/L, triglyceride level 2.3 mmol/L, low density lipo-
protein level  4.90 mmol/L and high density lipoprotein
values 1.00 mmol/L or if a person used lipid-lowering
medications. Participants were classified as smokers if they
were former or current smokers, irrespective of the number
of cigarettes smoked daily. Overweight or obesity was de-
fined as body mass index (BMI)  25 kg/m2. Exclusion cri-
teria were malignancy and any chronic inflammatory
disease.
The control group was composed of 182 individuals
who showed no evidence of CHD, CVD, PAD, T2DM, hy-
pertension, malignancy and chronic inflammatory diseases
based on laboratory and clinical checkup at ZUMC’s clin-
ics. The percentage of female vs. male participants in the
control group corresponded to the percentage in the case
group. Similarly, the age range and mean were approxi-
mately the same in the two groups.
All procedures were done in accordance with Hel-
sinki Declaration of 1975 and the study protocol was ap-
proved by the ethical Committee of Zvezdara University
Medical Center. All study participants signed the informed
consent.
Genetic analysis
Genomic DNA was isolated from peripheral blood or
from buccal swabs by DNeasy Blood & Tissue Kit
(Qiagen) according to the manufacturer’s recommenda-
tions. Isolated DNA was stored at 4 °C until further analy-
sis.
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For simultaneous detection of GSTM1 and GSTT1 ge-
notypes a multiplex polymerase chain reaction (multiplex
PCR) and real-time PCR were performed with primers de-
scribed by Voso and coworkers (Voso et al., 2002). As an
internal amplification control, primers for -globin gene
were used to exclude false negative results.
PCR mixture for multiplex PCR (total volume 50 L)
contained 2X Multiplex PCR Master Mix (2X-concen-
trated solution containing HotStart Taq DNA polymerase,
reaction buffer, MgCl2 and dNTP (Qiagen), 0.5 M of each
primer (Metabion) and 0.2 g of genomic DNA. Amplifi-
cation products from this reaction were separated on 3%
agarose gels, stained with ethidium bromide (0.5 /mL)
and visualized under UV light for determination of geno-
types. Subjects with GSTM1 and GSTT1 null genotypes did
not show amplification of fragments corresponding to 215
bp and 480 bp, respectively. An amplified -globin gene
fragment (110 bp) was observed in every PCR reaction as
an indicator of a successful reaction.
Instead of randomly re-genotyping 10% of samples
by the same multiplex PCR procedure to confirm the geno-
types, 50 samples were additionally genotyped by real-time
PCR and melting curve analysis. No discrepancies between
genotypes determined in duplicate were found. Reaction
mixes for real-time PCR were prepared according to the
manufacturer’s recommendations (for a total volume of 25
L): 2X Maxim SYBR Green/ROX qPCR Master Mix
(Fermentas Life Sciences), 0.35 M of each primer (Meta-
bion), <500 ng template DNA and nuclease-free water to
complete 25 l.
Statistical analysis
Chi-square (X2) and Student’s t-test were used to
compare demographics and clinical characteristics between
case and control groups. Allele and genotype frequencies
were estimated by allele counting method. Possible differ-
ences in allele and genotype frequencies between cases and
controls were determined by Pearson’s X2 test and Fisher’s
exact probability test. The risk of disease of examined ge-
netic polymorphisms was assessed by calculating odds ra-
tios (OR) and their 95% confidence intervals (CI). A P-
value < 0.05 was considered significant. Statistical analysis
was carried out using SPSS software (version 17.0). Enroll-
ment of 200 atherosclerotic patients and 182 healthy con-
trols achieved a 97.2% power to detect a significant differ-
ence in development of atherosclerosis between the
observed groups, at a two-tailed significance level of 0.05
using chi square test. Also, this sample size achieved a
99.3% power when we observed the frequency of GSTM1
and GSTT1 double null genotypes.
Results
The demographic and clinical characteristics of the
studied groups are shown in Table 1. There was no signifi-
cant difference between cases and controls in terms of age,
sex, obesity, hyperlipidemia and smoking. In contrast,
there were significantly more subjects with T2DM and hy-
pertension among patients with atherosclerosis than among
controls (P < 0.0001 for both variables).
A significant difference in GSTM1 null genotype
(phenotype) frequencies between cases and control patients
was observed (52.0 versus 34.1%). No association was
found between GSTT1 null genotype (phenotype) and dis-
ease but the risk approached significance (P=0.08) (Table
2). GSTM1/GSTT1 combined phenotype frequencies were
significantly different between cases and controls for
GSTM1 non-null/GSTT non-null and GSTM null/GSTT
null. The presence of both genes had a protective effect
(OR=0.55, 95%CI=0.37-0.83, P=0.005) whilst individuals
with double null genotypes had an approximate 8-fold in-
crease of the risk for atherogenesis (OR=8.14, 95%
CI=2.41-27.51, P<0.0001) (Table 3).
Discussion
It is well established that genetic factors play an im-
portant role in the pathogenesis of atherosclerosis and that
genetically susceptible individuals are likely to develop the
disease when exposed to endogenous and environmental
risk factors, among others.
OS is the result of overproduction of reactive oxygen
species and/or deficiency of antioxidant mechanisms and
depends on the balance between generation of ROS and en-
zymatic or non-enzymatic systems of antioxidative protec-
tion. Several factors, such as hypercholesterolemia, hyper-
tension, diabetes, obesity and aging are established risk
factors for atherosclerosis-based cardiovascular diseases
where OS is increased and antioxidant defenses are com-
promised.
GSTs, as antioxidant enzymes, represent the second
line of defense, which neutralizes lipid peroxidation prod-
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Table 1 - Demographic and clinical characteristic of atherosclerosis pa-
tients and controls.
Variables Patients
(N=200)
Controls
(N=182)
P
Age (years) 60.3  6.3 59.5  3.4 0.12
a
Gender, M/F N (%) 131/69
(65.5/34.5)
118/64
(64.8/35.3)
0.89b
Overweight or obese N
(%)
112 (56.0) 91 (50.0) 0.2b
Diabetes Mellitus Type
2 N (%)
140 (70.0) - <0.0001b
Hypertension N (%) 178 (89.0) - <0.0001b
Hyperlipidemia N (%) 170 (85.0) 142 (78.0) 0.07b
Smoker (current or for-
mer) N (%)
98 (49.0) 78 (42.8) 0.27b
Data for age are presented as mean  SD, N: number of subjects; P: proba-
bility; aStudent’s t-test; bX2 test
ucts (Sharma et al., 2006). Given the high global preva-
lence of CVDs, the number of studies dealing with the
effects of GST polymorphisms on atherosclerosis are actu-
ally quite limited. Not only are the studies insufficient in
number, but also the results are diverse and sometimes con-
tradictory, which is in part the consequence of ethnic and
geographical specificities of the studied populations.
A recent analysis of functional genetic differences in
GST enzymes among six human groups with different eth-
nic background has shown that ethnicity strongly affects
the genetic variability of GST enzymes. These data empha-
size that human populations have different structure of de-
toxification genes, suggesting that ethnic differences influ-
ence disease risk or response to drugs (Hiragi et al., 2011;
Polimanti et al., 2013).
In four large studies and meta-analyses in Danes,
copy number variation (CNV) in GSTM1 and GSTT1 was
not associated with risk of any ischemic vascular event or
with markers of inflammation (Nørskov et al., 2011). A
meta-analysis performed by Wang et al. (2010) suggested
that the GSTM1 null genotype may slightly increase the risk
of coronary heart disease and that interaction between unfa-
vorable GSTs genotypes may exist.
In a Turkish population, GSTT1 and GSTM1 null ge-
notypes, together with hypertension, were seen to play a
significant role in the pathogenesis of ischemic stroke (Tür-
kanoglu et al., 2010). It has also been reported that the
GSTT1 null genotype is associated with premature morbid-
ity and mortality in individuals with T2DM (Doney et al.,
2005), and a very clear association has been shown between
the GSTT1 null genotype and combined GSTM1 and
GSTT1 null genotypes, and complications related to diabe-
tes such as atherosclerosis (Ramprasath et al., 2011; Santl
Letonja et al., 2012).
In the present study, a significant difference in
GSTM1 genotype distribution was found between cases
and controls and homozygous GSTM1 deletion signifi-
cantly increased the risk of clinical manifestations of ath-
erosclerosis. This risk increase was even more pronounced
in individuals with the deletion of both genes.
The level of expression of GSTs is a crucial factor in
determining the sensitivity of cells to a broad spectrum of
toxic chemicals. GSTs are highly expressed enzymes with a
complex transcriptional and posttranscriptional regulation
and with structurally very different inducers, many of them
being substrates at the same time. Patients with genetic
variations that result in the absence or very little corre-
sponding enzyme, show more severe clinical as well as bio-
chemical and cellular phenotypes than patients carrying
variations that still produce some residual protein amounts
and enzyme activity (Olsen et al., 2013). GST induction is
considered part of an adaptive response mechanism to che-
mical stress caused by electrophiles. Since GSTs produc-
tion determines an individual’s ability to detoxify products
of ROS, especially endogenous products of oxidative dam-
age, double deletions of GSTM1 and GSTT1 resulting in
lower levels of GSTs are likely to play an important role in
the development of diseases related to oxidative stress, in-
cluding atherosclerosis.
A major contribution of a single gene is very unlikely
in multifactorial diseases such as atherosclerosis, where a
large number of pathogenetic mechanisms lead to a clinical
outcome (Dalepiane et al., 2007). Thus effects of a loss-of-
function polymorphism alone are probably not sufficient to
influence the progression of atherosclerosis, but the accu-
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Table 2 - GSTM1 and GSTT1 phenotype frequencies in patient and control groups.
Phenotypes Patients/(200) N (%) Controls (182) N (%) OR 95%CI P
GSTM1
non-null (+/+, +/-) 96 (48) 120 (65.9)
null (-/-) 104 (52) 62 (34.1) 2.1 1.39-3.17 0.0004
GSTT1
non-null (+/+, +/-) 154(77) 153 (84.1)
null (-/-) 46 (23) 29 (15.9) 1.57 0.94-2.64 0.08
N: number of subjects; OR: odds ratio; 95%CI: 95% confidence interval; P: probability
Table 3 - Odds ratio analysis of combined GSTM1/GSTT1 phenotypes in patients and controls.
GSTM1/GSTT1 phenotypes Patients (200) N (%) Controls (182) N (%) OR 95%CI P
Non-null/Non-null 74 (37) 94 (51.7) 0.55 0.37-0.83 0.005
Non-null/Null 22 (11) 26 (14.3) 0.74 0.40-1.36 0.417
Null/Non-null 80 (40) 59 (32.4) 1.39 0.91-2.12 0.152
Null/Null 24 (12) 3 (1.6) 8.14 2.41-27.51 0.0001
N: Number of subjects; OR: odds ratio; 95%CI: 95% confidence interval; P: probability
mulation of “unfavorable” oxidative stress-associated gene
polymorphisms is likely associated with the evolution of its
clinical manifestations (Katakami et al., 2009).
From the present study, it seems that GSTM1 null and
combined GSTM1/GSTT1 null phenotypes are strong risk
factors for atherogenesis in the Serbian population. It must
be emphasized however, that the statistical power to detect
association may be limited due to the relatively small sam-
ple size of both atherosclerotic patients (200) and controls
(182), leading to false positive results. Recruitment and
survival bias cannot be ruled out either, in particular among
controls who may develop atherosclerosis in the future
(Guo et al., 2013). A study on a larger group of atheros-
clerotic patients, with and without diabetes mellitus should
also be considered in order to avoid this confounding ele-
ment.
In conclusion, coupled deletions of GSTM1 and
GSTT1 genes may play a significant role in the etiopatho-
genesis of atherosclerosis and may represent a useful
marker in the prediction of disease susceptibility in Serbs.
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